

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.:126, 3/2, 75C, PARK STREET,3RD FLOOR KAMDHENU BUILDING ,KOLKATA -700016

Email: shreeganeshbiotechindiaLtd@gmail.com Website: www.shreeganeshbiotech.club

Date: 01.02.2022

To,
Listing Department,
BSE Limited,
P J Tower, Dalal
Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock
Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange of
India Limited
Vibgyor Towers, 4th floor, Plot No
C 62, Opp. Trident Hotel Bandra
Kurla Complex, Bandra (E),
Mumbai – 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREEGANES

Dear Sir / Madam,

Sub: Rectification in our previous upload of Unaudited Results dated 01.02.2022

As per our previous upload in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have uploaded results for quarter ended as on 31.12.2021 in which we have by mistake uploaded the Limited Review Report of wrong quarter henceforth rectifying the same.


Kindly take the same on your record and oblige.

Thanking You.

Yours faithfully

For, SHREE GANESH BIO-TECH (INDIA) LIMITED

Director/Authorised Signatory



SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.:126, 3/2, 75C, PARK STREET,3RD FLOOR KAMDHENU BUILDING ,KOLKATA -700016

Email: shreeganeshbiotechindiaLtd@gmail.com Website: www.shreeganeshbiotech.club

Date: 01.02.2022

To,
Listing Department,
BSE Limited,
P J Tower, Dalal
Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock
Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange of
India Limited
Vibgyor Towers, 4th floor, Plot No
C 62, Opp. Trident Hotel Bandra
Kurla Complex, Bandra (E),
Mumbai – 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREEGANES

Dear Sir / Madam,

Sub: Unaudited Financial Result for quarter ending 31st December 2021 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith unaudited financial result for quarter ended 31st December 2021.

Kindly take the same on your record and oblige.

Thanking You.

Yours faithfully
For, SHREE GANESH BIO-TECH (INDIA) LIMITED

Director/Authorised Signatory



Shree Ganesh Biotech (India) Ltd

CIN:- L70101WB1982PLC121196

Regd. Office: 126/3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016

Email - shreeganeshbiotechindia@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended December 31, 2021

Sl No.	Particulars						(Rs. In Lacs)
		Quarter Ended 31 Dec'2021	Quarter Ended 30 Sept'2021	Quarter Ended 31 Dec'2020	Nine Months Ended 31 Dec'2021	Nine Months Ended 31 Dec'2020	Year Ended 31 Mar 2021
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
(a)	Revenue from Operations	1,902.90	1,795.99	784.23	5,250.50	795.58	1,721.38
(b)	Other Income	0.23	0.19	-	5.06	-	-
	Total Income from Operations (Net)	1,903.13	1,796.18	784.23	5,255.56	795.58	1,721.38
2	Expenses						
(a)	Cost of material consumed	-	-	-	-	-	-
(b)	Purchase of stock in trade	1,801.14	1,696.44	847.12	4,983.49	854.82	1,632.98
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	9.59	(103.44)	-	(103.44)	-
(d)	Employee benefit expense	6.29	6.06	3.94	18.25	5.88	7.92
(e)	Finance Costs	-	-	-	-	-	0.04
(f)	Depreciation and Amortization Expense	-	-	-	-	-	0.06
(g)	Other expenses	0.69	1.68	-	8.18	9.66	9.67
	Total Expenses	1,808.12	1,713.77	747.62	5,009.92	766.92	1,650.67
3	Profit / (Loss) from operations before exceptional items and Tax (1-2)	95.01	82.41	36.61	245.64	28.66	70.71
4	Exceptional Items						27.90
5	Profit / (Loss) before Tax (3 ± 4)	95.01	82.41	36.61	245.64	28.66	42.81
6	Tax Expense						11.13
7	Profit / (Loss) after tax (5 - 6)	95.01	82.41	36.61	245.64	28.66	31.68
8	Other comprehensive income (Net of Tax)						
A.	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified profit or loss	-	-	-	-	-	-
B.	(i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
9	Total comprehensive income (7 ± 8)	95.01	82.41	36.61	245.64	28.66	31.68
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	1,993.12	1,993.12	1,993.12	1,993.12	1,993.12	1,993.12
11	Other Equity						3,786.09
12	Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised):						
(a)	Basic	0.48	0.41	0.18	1.23	0.14	0.16
(b)	Diluted	0.48	0.41	0.18	1.23	0.14	0.16

Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 01, 2022. The Statutory Auditors have carried out a limited review of the above financial result.
- Company has only one segment and hence no separate segment result has been given.
- Provision for taxation if any will be made at the year end.
- The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Kolkata

Date : 01st February, 2022





Limited Review Report

To
The Board of Directors of
SHREE GANESH BIOTECH (INDIA) LIMITED
Kolkata


We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SHREE GANESH BIOTECH (INDIA) LIMITED** ("the Company"), for the Quarter ended on December 31, 2021 and year to date result for the period from 01 April, 2021 to 31 December, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bipin & Co.
Chartered Accountants
FRN: 101509 W


CA Amit Shah (Partner)
M. No.: 126337
UDIN: 22126337AAAABD4487
Place: Vadodara
Date: 01.02.2022

